| Filed On | Filing |
|---|---|
| 20 Jun 2024 |
8-K/A: Submission of Matters to a Vote of Security Holders
In the Original Report, the Company disclosed the voting results for the proposals submitted to a stockholder vote at the Annual Meeting. The Company subsequently learned of a calculation error in the results reported to the Company for ... |
| 02 Feb 2024 |
8-K/A: Departure/Election of Directors or Officers; Compensation
SPECIFIC TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE DISCLOSURE OF SUCH INFORMATION WOULD CONSTITUTE A CLEARLY UNWARRANTED INVASION OF PERSONAL PRIVACY. THESE REDACTED TERMS HAVE BEEN MARKED IN THIS EXHIBIT WITH THREE ASTERISKS: [***] |
| 23 Oct 2023 |
8-K/A: Submission of Matters to a Vote of Security Holders
As previously disclosed, at the 2023 Annual Meeting, the Company’s stockholders voted on a non-binding advisory basis on the frequency of the advisory vote on the compensation of the Company’s named executive officer (the “Say-on-Frequen... |
| 05 Aug 2022 |
8-K/A: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders +1 more
(a) Eligible Award Recipients. Employees, Directors and Consultants are eligible to receive Awards. |
| 16 Sep 2021 |
8-K/A: Entry into a Material Definitive Agreement
“On September 15, 2021, Vaxart, Inc. (“Vaxart” or the “Company”) entered into a Controlled Equity OfferingSM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (“Cantor”) and B. Riley Securities Inc. (“B. Riley” and, to... |
| 08 Jun 2018 |
8-K/A: Financial Statements and Exhibits
Severance Benefit Plan and Form of Severance Benefit Plan Participation Notice. |
| 27 Apr 2018 |
8-K/A: Financial Statements and Exhibits
The following unaudited pro forma condensed combined financial statements give effect to the merger between Aviragen Therapeutics, Inc. (“Aviragen”) and pre-merger Vaxart, Inc. (“Private Vaxart”) and were prepared in accordance with U.S.... |
| 02 Apr 2018 |
8-K/A: Financial Statements and Exhibits
We have audited the accompanying balance sheets of Vaxart Biosciences, Inc. (the Company) as of December 31, 2017 and 2016, and the related statements of operations and comprehensive loss, stockholders’ deficit and cash flows for the yea... |
| 23 Jan 2013 |
8-K/A: Completion of Acquisition or Disposition of Assets
Consolidated Statements of Stockholders’ Equity and Comprehensive Income |
| 12 Jul 2012 |
8-K/A: Departure/Election of Directors or Officers; Compensation
On July 6, 2012, Nabi Biopharmaceuticals (the “Company”) notified Paul Kessler, M.D. and Matthew Kalnik, Ph.D. that their employment with the Company would be terminated effective August 5, 2012 as the Company continues to reduce its ope... |
| 18 Oct 2011 |
8-K/A: Submission of Matters to a Vote of Security Holders
At the Company’s Annual Meeting, the Company’s stockholders voted on, among other matters, a non-binding proposal regarding the frequency of future stockholder advisory votes on executive compensation. As previously reported, the Company... |
| 27 May 2010 |
8-K/A: Submission of Matters to a Vote of Security Holders
The following provides a summary of votes cast for the proposals on which the stockholders of Nabi Biopharmaceuticals (the “Company”) voted at the annual meeting of stockholders held on May 20, 2010 (the “Annual Meeting”): |
| 16 Mar 2007 |
8-K/A: Results of Operations and Financial Condition
Boca Raton, Florida, March 15, 2007 – Nabi Biopharmaceuticals (Nasdaq: NABI) announced the filing of its Annual Report on Form 10-K for the fiscal year ended December 30, 2006 and re-released its 2006 fourth quarter and full-year financi... |
| 16 Mar 2007 |
8-K/A: Results of Operations and Financial Condition
Boca Raton, Florida, March 15, 2007 – Nabi Biopharmaceuticals (Nasdaq: NABI) announced the filing of its Annual Report on Form 10-K for the fiscal year ended December 30, 2006 and re-released its 2006 fourth quarter and full-year financi... |
| 07 Oct 2003 |
8-K/A: Financial Statements and Exhibits
We consent to the incorporation by reference in the Registration Statement (Form S-3 No. 333-42188) and in the related Prospectus of Nabi Biopharmaceuticals and the Registration Statement (Forms S-8 No. 333-38868 and No. 333-38864) perta... |
| 07 Oct 2003 |
8-K/A: Financial Statements and Exhibits
We consent to the incorporation by reference in the Registration Statement (Form S-3 No. 333-42188) and in the related Prospectus of Nabi Biopharmaceuticals and the Registration Statement (Forms S-8 No. 333-38868 and No. 333-38864) perta... |
| 05 Apr 2002 |
8-K/A: Financial Statements and Exhibits
PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT UNDER RULE 24(B)-2. THE LOCATION OF THOSE OMITTED PORTIONS IS DENOTED BY ASTERISKS. |
| 24 Sep 2001 |
8-K/A: Other Events
PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT UNDER RULE 24(B)-2. THE LOCATION OF THOSE OMITTED PORTIONS IS DENOTED BY ASTERISKS. |
Loading...